David Hoang
Stock Analyst at Deutsche Bank
(3.34)
# 950
Out of 5,179 analysts
49
Total ratings
44.74%
Success rate
5.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATAI AtaiBeckley | Initiates: Buy | $12 | $3.35 | +258.21% | 1 | Mar 27, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $56 → $90 | $54.48 | +65.20% | 4 | Mar 10, 2026 | |
| APGE Apogee Therapeutics | Initiates: Buy | $103 | $77.82 | +32.36% | 1 | Dec 10, 2025 | |
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $29.39 | +53.11% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $290.10 | -3.48% | 2 | Oct 17, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $43 | $47.31 | -9.11% | 1 | Sep 26, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $26.54 | +35.64% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $19.97 | -39.91% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $20.75 | +68.67% | 5 | May 21, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $18.16 | +70.70% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $8.37 | +676.58% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $176 | $156.35 | +12.57% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $128.32 | +23.13% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.26 | +209.73% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $7.11 | +125.04% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.96 | +304.04% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $317.36 | -30.68% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $57.78 | +38.46% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $0.35 | +765.80% | 1 | Dec 7, 2022 |
AtaiBeckley
Mar 27, 2026
Initiates: Buy
Price Target: $12
Current: $3.35
Upside: +258.21%
Xenon Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $56 → $90
Current: $54.48
Upside: +65.20%
Apogee Therapeutics
Dec 10, 2025
Initiates: Buy
Price Target: $103
Current: $77.82
Upside: +32.36%
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $29.39
Upside: +53.11%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $290.10
Upside: -3.48%
Spyre Therapeutics
Sep 26, 2025
Initiates: Buy
Price Target: $43
Current: $47.31
Upside: -9.11%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $26.54
Upside: +35.64%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $19.97
Upside: -39.91%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $20.75
Upside: +68.67%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $18.16
Upside: +70.70%
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $8.37
Upside: +676.58%
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $156.35
Upside: +12.57%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $128.32
Upside: +23.13%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $2.26
Upside: +209.73%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $7.11
Upside: +125.04%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $3.96
Upside: +304.04%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $317.36
Upside: -30.68%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $57.78
Upside: +38.46%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $0.35
Upside: +765.80%